South Andrew M, Maestretti Lynn, Kambham Neeraja, Grimm Paul C, Chaudhuri Abanti
Section of Nephrology, Department of Pediatrics, Wake Forest School of Medicine, Winston Salem, NC, USA.
Cardiovascular Sciences Center, Wake Forest School of Medicine, Winston Salem, NC, USA.
Pediatr Transplant. 2017 Nov;21(7). doi: 10.1111/petr.13035. Epub 2017 Aug 22.
Pediatric renal transplant recipient survival continues to improve, but ABMR remains a significant contributor to graft loss. ABMR prognostic factors to guide treatment are lacking. C4d staining on biopsies, diagnostic of ABMR, is associated with graft failure. Persistent C4d+ on follow-up biopsies has unknown significance, but could be associated with worse outcomes. We evaluated a retrospective cohort of 17 pediatric renal transplant patients diagnosed with ABMR. Primary outcome at 12 months was a composite of ≥50% reduction in eGFR, transplant glomerulopathy, or graft failure. Secondary outcome was the UPCR at 12 months. We used logistic and linear regression modeling to determine whether persistent C4d+ on follow-up biopsy was associated with the outcomes. Forty-one percent reached the primary outcome at 12 months. Persistent C4d+ on follow-up biopsy occurred in 41% and was not significantly associated with the primary outcome, but was significantly associated with the secondary outcome (estimate 0.22, 95% CI 0.19-0.25, P < .001), after controlling for confounding factors. Persistent C4d+ on follow-up biopsies was associated with a higher UPCR at 12 months. Patients who remain C4d+ on follow-up biopsy may benefit from more aggressive or prolonged ABMR treatment.
小儿肾移植受者的生存率持续提高,但抗体介导的排斥反应(ABMR)仍是导致移植肾丢失的重要因素。目前缺乏指导治疗的ABMR预后因素。活检时C4d染色可诊断ABMR,与移植肾失败相关。随访活检中持续存在的C4d阳性意义不明,但可能与更差的预后相关。我们评估了17例诊断为ABMR的小儿肾移植患者的回顾性队列。12个月时的主要结局是估算肾小球滤过率(eGFR)降低≥50%、移植性肾小球病或移植肾失败的复合结局。次要结局是12个月时的尿蛋白肌酐比值(UPCR)。我们使用逻辑回归和线性回归模型来确定随访活检中持续存在的C4d阳性是否与这些结局相关。41%的患者在12个月时达到主要结局。随访活检中41%出现持续C4d阳性,与主要结局无显著相关性,但在控制混杂因素后,与次要结局显著相关(估计值0.22,95%置信区间0.19 - 0.25,P <.001)。随访活检中持续C4d阳性与12个月时较高的UPCR相关。随访活检仍为C4d阳性的患者可能从更积极或延长的ABMR治疗中获益。